Navigation Links
Study questions assumptions about human sensitivity to biological motion
Date:10/17/2007

Rockville, MD -- Humans may not be any more sensitive in detecting biological motion compared with nonbiological motion, concludes a study recently published in Journal of Vision, an online, free-access publication of the Association for Research in Vision and Ophthalmology (ARVO).

Dr Eric Hiris of St. Mary's College of Maryland, (St Mary's City, MD, US) contends that although many papers on the subject begin with statements to the effect that humans are particularly sensitive in detecting point-light biological motion, little research has been performed that supports this.

Previous research in this area, according to Hiris, generally has failed to take into account form information in biological motion and/or has used masks that were less than optimal for biological motion.

Using point-light displays, Hiris's study, described in "Detection of biological and nonbiological motion," (http://www.journalofvision.org/7/12/4/) compared biological motion to nonbiological motion with and without an underlying form; equated the effectiveness of masks across displays; and presented targets of various sizes within a constant-sized mask area to determine if mask density predicted detection performance.

Hiris concludes that the resulting evidence does not show that humans are better able to detect biological motion if nonbiological motion contains an underlying form, and, in some cases, even if it does not.

"Do researchers sometimes state conclusions in ways that go beyond the data?" asks Hiris. "Specifically, what do researchers mean when they say we're 'highly sensitive' to some aspect of motion? These findings may highlight the need to be careful about how we couch our conclusions."


'/>"/>

Contact: Joanne Olson
jolson@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Page: 1

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: